Pharmacotherapies designed to suppress TNFR1-mediated or augment TNFR2-mediated effects of TNFα may provide antiseizure and disease-modifying effects after central nervous system infection. This evidence concerns the gene TNFRSF1B and central nervous system infectious disorder.